On October 9, HBM HOLDINGS-B fell 5.09% in regular trading, trading at 11.16 HKD, with Turnover of 12.73 million HKD.

The stock has extended its decline for a third consecutive session, with the broader biotechnology sector remaining weak amid sustained pressure on global biotech risk appetite. Sector peers also traded lower, with Cansino Biologics down 5.17%, Innovent Biologics down 1.84%, Akeso down 2.65%, Beone Medicines down 2.91%, while 3SBIO edged up 0.27%.

HBM Holdings is an investment holding company engaged in the development of innovative therapies in the fields of tumor immunology and immunological diseases. Its products include batoclimab, HBM9378, HBM7020, TCE programs, prusobizumab, and others, targeting conditions such as generalized myasthenia gravis, chronic obstructive pulmonary disease, asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors. The company provides next-generation antibody and biological solutions through its proprietary platforms Harbour Mice, HBICE, HBICA, and monoclonal B-cell screening.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)